Last reviewed 2026-05-27 · How we verify

Risperidone Long Acting

Risperidone Long Acting is a Atypical antipsychotic Small molecule drug developed by Dartmouth-Hitchcock Medical Center. It is currently FDA-approved for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder. Also known as: Risperdal Consta.

Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.

Risperidone Long Acting, also known as Risperdal Consta, is a small molecule serotonin 2a (5-HT2a) receptor antagonist used to treat conditions such as bipolar disorder and schizophrenia. It is a long-acting formulation of the drug risperidone, which is classified as an antagonist and works by blocking the action of the 5-hydroxytryptamine receptor 2A.

At a glance

Mechanism of action

Risperidone antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The long-acting formulation provides sustained drug delivery via intramuscular injection, improving medication adherence in patients with schizophrenia and bipolar disorder.

Approved indications

• Schizophrenia
• Bipolar I disorder (acute mania and maintenance)
• Irritability associated with autism spectrum disorder

Common side effects

• Injection site pain or reaction
• Weight gain
• Extrapyramidal symptoms (tremor, rigidity, akathisia)
• Prolactin elevation (galactorrhea, amenorrhea)
• Sedation
• Orthostatic hypotension
• Metabolic syndrome

Key clinical trials

• Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
• Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
• High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone (PHASE4)
• Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
• A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities (PHASE4)
• A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
• A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Risperidone Long Acting CI brief — competitive landscape report
• Risperidone Long Acting updates RSS · CI watch RSS
• Dartmouth-Hitchcock Medical Center portfolio CI

Frequently asked questions about Risperidone Long Acting

Related

• Drug class: All Atypical antipsychotic drugs
• Target: All drugs targeting Dopamine D2 receptor, Serotonin 5-HT2A receptor
• Manufacturer: Dartmouth-Hitchcock Medical Center — full pipeline
• Therapeutic area: All drugs in Psychiatry
• Indication: Drugs for Schizophrenia
• Indication: Drugs for Bipolar I disorder (acute mania and maintenance)
• Indication: Drugs for Irritability associated with autism spectrum disorder
• Also known as: Risperdal Consta

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing